hrp0084lbp-1257 | Late Breaking Posters | ESPE2015

Prepubertal and Pubertal Predictors of Semen Quality in a Prospective Cohort Study of Russian Young Men: Focus on Endocrine-Disrupting Chemicals

Sergeyev Oleg , Minguez-Alarcon Lidia , Hauser Russ , Williams Paige L , Burns Jane S , Korrick Susan A , Dikov Yury , Smigulina Liudmila , Revich Boris , Lee Mary M

Background: We are not aware of other longitudinal cohort studies of boys with prepubertal assessment of exposure to endocrine-disrupting chemicals (EDCs) and annual long term follow-up of growth and puberty to evaluate semen quality.Objective: To describe semen quality and explore associations of prepubertal serum concentrations of organochlorine compounds and pubertal measures with semen parameters in an ongoing longitudinal cohort study of Russian boy...

hrp0082s2.3 | Endocrine Cancer Syndromes: An Update | ESPE2014

DICER1 Syndrome: A Review of the Syndrome with a Focus on Endocrine Aspects

Foulkes William

Background: DICER1, a ribonuclease, cleaves non-coding small RNA precursors to generate mature microRNAs (miRNAs), of ~21 nucleotides in length. MiRNAs alter gene expression post-transcriptionally by directly binding to mRNA transcripts and subsequently down-regulating gene expression. It is estimated that expression of ~30–70% of all mammalian protein-coding genes are regulated in this manner.Method: Sequencing of DICER1 in various tumors, accompan...

hrp0082s5.2 | Novel Insights into Hypoadrenalism | ESPE2014

Adrenarche: Coming of Age in the Era of Genomics and Metabolomics

Rainey William

The human adrenal cortex produces a wide range of steroids that includes aldosterone, cortisol and a variety of 19 carbon (C19) steroids; the most studied being DHEA. In humans, adrenarche is the endocrine developmental process manifested by an increased adrenal output of DHEA. This phenomenon corresponds with the expansion of the zona reticularis of the adrenal gland. However, the physiological mechanisms that trigger adrenarche remain elusive. Our research focuses...

hrp0094pl2 | Coming soon: new drugs for treatment of youth with type 2 diabetes | ESPE2021

New Drugs for Youth with Type 2 Diabetes

Tamborlane William

Metformin was the first and only drug approved in 1999 for use in youth with type 2 diabetes (T2D) based on a small, randomized clinical trial. Insulin was also approved but this was based only on the effective use of insulin in children with T1D. For more than 20 years, no new drugs had been approved for use in pediatric T2D based on a randomized study. A major reason why many of the new drugs have not been approved in pediatrics is that adolescents with T2D are difficult to ...

hrp0086p1-p565 | Perinatal Endocrinology P1 | ESPE2016

Different Long-term Neurodevelopmental Outcomes in Very Preterm Versus Very-low-birth-weight Infants

Hollanders Jonneke J , Schaefer Nina , van der Pal Sylvia M , Rotteveel Joost , Finken Martijn J J

Background: Birth weight (BW) is often used as a proxy for gestational age (GA) by studies on preterm birth. Recent data indicate that the terms very-low-birth-weight (VLBW; BW <1500 g) and very preterm (VP; GA <32 weeks) birth are not equivalent with regard to perinatal outcomes and postnatal growth up until final height. It is unknown whether the differences between these terms could be extended to long-term neurodevelopmental outcomes.Objectiv...

hrp0084fc10.5 | Perinatal Endocrinology | ESPE2015

Lack of Association between Transient Hypothyroxinaemia of Prematurity and Neurodevelopmental and Behavioral Outcomes in Young Adulthood

Hollanders Josephina J , Israels Joel , van der Pal Sylvia M , Rotteveel Joost , Finken Martijn J J

Background: Preterm newborns are at risk of becoming transiently hypothyroxinaemic, which has been associated with neurodevelopmental impairments in childhood. It is not known whether these associations persist into adulthood.Objective and hypotheses: We studied the relation between transient hypothyroxinaemia of prematurity and IQ, neuromotor functioning and problem behaviour at young adult age.Method: This was a prospective study...

hrp0094p1-173 | Growth Hormone and IGFs B | ESPE2021

Growth hormone receptor 6Ω pseudoexon activation: a novel cause of severe growth hormone insensitivity

Cottrell Emily , Maharaj Avinaash , Williams Jack , Chatterjee Sumana , Cirillo Grazia , Giudice Emanuele Miraglia del , Festa Adalgisa , Palumbo Stefania , Capalbo Donatella , Salerno Mariacarolina , Pignata Claudio , Savage Martin O. , Schilbach Katharina , Bidlingmaier Martin , Hwa Vivian , Metherell Louise A. , Grandone Anna , Storr Helen L. ,

Context: Severe forms of growth hormone insensitivity (GHI) are characterised by extreme short stature, dysmorphism and metabolic anomalies. They are classically caused by homozygous or compound heterozygous mutations of the growth hormone receptor gene (GHR). Genetic analysis traditionally focuses on the exonic regions of genes that encode proteins rather than the intervening non-coding sequences. These seldom explored non-coding regions may harbour ...

hrp0092p2-107 | Fat, Metabolism and Obesity | ESPE2019

Childhood Obesity and Iron Metabolism

Sousa Bebiana , Galhardo Júlia

Introduction: Hypoferraemia is the most common nutritional deficiency worldwide and a leading cause of potential developmental disorders in children. Obesity seems to be associated with this condition, but it is still unclear if it is caused either by depleted iron stores, diminished availability, or both.Aim: To analyse the relationships between childhood obesity, iron metabolism and inflammation....

hrp0092p3-132 | Fetal, Neonatal Endocrinology and Metabolism (to include Hypoglycaemia) | ESPE2019

Recurrent Apnea in a Boy Suffering from Congenital Hyperinsulinism in the Course of Diazoxide Treatment

Nowaczyk Jedrzęj , Kucharska Anna

Congenital hyperinsulinism (CHI) is rare disease which prevalence is estimated as 1:2500 to 1:50000 born newborns. Main reason of the disease are genetic mutations in genes responsible for regulation of insulin secretion. First line treatment is diazoxide therapy.Our patient was diagnosed with CHI at the age of 2 months. Biochemical tests prooved diagnosis of CHI. He presented lack of negative feedback and secreted pathologic amount of insulin – dur...

hrp0084fc13.6 | Thyroid | ESPE2015

TRIAC Treatment of Allan-Herndon-Dudley Syndrome (AHDS) due to Defects in Thyroid Hormone Transporter MCT8

Iglesias A , Gomez-Gila A L , Casano P , del Pozo J , de Mingo M C , Pons N , Calvo F , Obregon M J , Bernal J , Moreno J C

Background: AHDS is a devastating disease caused by defects in the thyroid hormone (TH) transporter MCT8. Endocrine expression is heralded by systemic hyperthyroidism with elevated serum T3, mildly increased TSH and decreased T4. However, the brain is hypothyroid, causing severe psychomotor retardation. Therapeutic attempts with PTU+levothyroxine or the T3-analogue DITPA could normalize TH derangements but without any neurological improvement. ...